Institutionen för farmaci

Institutionen för farmaci Forskning Farmakometri Publikationer

This page in English

Senaste publikationer

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Ayoun Alsoud, Rami; Svensson, Robin J.; Svensson, Elin; Gillespie, Stephen H. H. et al.

Ingår i Frontiers in Pharmacology, 2023.

DOI för Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development Ladda ner fulltext (pdf) av Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Open access
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Madathil Krishnan, Sreenath; Friberg, Lena; Mercier, Francois; Zhang, Rong et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 851-858, 2023.

DOI för Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study Ladda ner fulltext (pdf) av Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Open access
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

Centanni, Maddalena; Thijs, Abel; Desar, Ingrid; Karlsson, Mats O. et al.

Ingår i Clinical and Translational Science, s. 73-84, 2023.

DOI för Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors Ladda ner fulltext (pdf) av Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

Open access
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Svensson, Robin J.; Ooi, Qing Xi; Friberg, Lena E.; Maharaj, Narendra et al.

Ingår i CPT, s. 154-167, 2023.

DOI för Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity Ladda ner fulltext (pdf) av Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Open access
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Mockeliunas, Laurynas; Faraj, Alan; Van Wijk, Rob C; Upton, Caryn M. et al.

Ingår i Frontiers in Pharmacology, 2023.

DOI för Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development Ladda ner fulltext (pdf) av Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Open access
Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Susanto, Budi O.; Svensson, Elin M.; te Brake, Lindsey; Aarnoutse, Rob E. et al.

Ingår i International Journal of Antimicrobial Agents, 2023.

DOI för Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin Ladda ner fulltext (pdf) av Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Open access
Clinical standards for the management of adverse effects during treatment for TB

Singh, K. P.; Carvalho, A. C. C.; Centis, R.; D'Ambrosio, L. et al.

Ingår i The International Journal of Tuberculosis and Lung Disease, s. 506-519, 2023.

DOI för Clinical standards for the management of adverse effects during treatment for TB Ladda ner fulltext (pdf) av Clinical standards for the management of adverse effects during treatment for TB

Open access
Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli

Bahnasawy, Salma M.; Skorup, Paul; Hanslin, Katja; Friberg, Lena et al.

Ingår i Cytokine, 2023.

DOI för Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli Ladda ner fulltext (pdf) av Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli

Open access
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Bukkems, Laura H.; Versloot, Olav; Cnossen, Marjon H.; Jönsson, Siv et al.

Ingår i Thrombosis and Haemostasis, s. 317-325, 2023.

DOI för Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A Ladda ner fulltext (pdf) av Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Open access
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Faraj, Alan; Van Wijk, Rob C; Neuman, Linda; Desai, Shraddha et al.

Ingår i CPT, s. 977-987, 2023.

DOI för Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy Ladda ner fulltext (pdf) av Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Open access
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

Faraj, Alan; Le Moan, Natacha; Gorina, Eduard; Blouse, Grant E. E. et al.

Ingår i Advances in Therapy, s. 3739-3750, 2023.

DOI för Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients Ladda ner fulltext (pdf) av Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

Open access
Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Llanos-Paez, Carolina; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 297-314, 2023.

DOI för Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials Ladda ner fulltext (pdf) av Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Open access
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance

Frenk, Sammy; Temkin, Elizabeth; Lurie-Weinberger, Mor N.; Keren-Paz, Alona et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 934-943, 2022.

DOI för Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Grisic, Ana-Marija; Xiong, Wenyuan; Tanneau, Lénaïg; Jönsson, Siv et al.

Ingår i Clinical Cancer Research, s. 1363-1371, 2022.

DOI för Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab Ladda ner fulltext (pdf) av Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Open access
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis

Mockeliunas, Laurynas; Keutzer, Lina; Sturkenboom, Marieke G. G.; Bolhuis, Mathieu S. et al.

Ingår i Pharmaceutics, 2022.

DOI för Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis Ladda ner fulltext (pdf) av Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis

Open access
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

De Jager, Veronique; Gupte, Nikhil; Nunes, Silvia; Barnes, Grace L. et al.

Ingår i American Journal of Respiratory and Critical Care Medicine, s. 1228-1235, 2022.

DOI för Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections

Nutman, Amir; Temkin, Elizabeth; Lellouche, Jonathan; Rakovitsky, Nadya et al.

Ingår i Clinical Microbiology and Infection, s. 73-78, 2022.

DOI för In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia

Gkoufa, Aikaterini; Sou, Tomas; Karaiskos, Ilias; Routsi, Christina et al.

Ingår i International Journal of Antimicrobial Agents, 2022.

DOI för Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Ruth, Mike Marvin; Raaijmakers, Jelmer; van den Hombergh, Erik; Aarnoutse, Rob et al.

Ingår i Clinical Microbiology and Infection, s. 448.e1-448.e7, 2022.

DOI för Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics Ladda ner fulltext (pdf) av Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Open access
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application

Van Wijk, Rob C; Simonsson, Ulrika S. H.

Ingår i CPT, s. 991-1001, 2022.

DOI för Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application Ladda ner fulltext (pdf) av Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application

Open access
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Llanos-Paez, Carolina C.; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Ingår i Pharmaceutical research, s. 1779-1787, 2022.

DOI för Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients Ladda ner fulltext (pdf) av Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Open access
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Keutzer, Lina; You, Huifang; Farnoud, Ali; Nyberg, Joakim et al.

Ingår i Pharmaceutics, 2022.

DOI för Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin Ladda ner fulltext (pdf) av Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Open access
Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings

Minichmayr, Iris; Kappetein, Suzanne; Brill, Margreke J. E.; Friberg, Lena

Ingår i Antibiotics, 2022.

DOI för Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings Ladda ner fulltext (pdf) av Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings

Open access
A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study

Keutzer, Lina; Akhondipour, Yasamin; Forsman, Lina Davies; Simonsson, Ulrika S. H.

Ingår i CPT, s. 628-639, 2022.

DOI för A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study Ladda ner fulltext (pdf) av A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study

Open access
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance

Yin, Anyue; van Hasselt, Johan G. C.; Guchelaar, Henk-Jan; Friberg, Lena et al.

Ingår i Scientific Reports, 2022.

DOI för Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance Ladda ner fulltext (pdf) av Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance

Open access
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma

Kotani, Naoki; Dolton, Michael; Svensson, Robin J.; Ribbing, Jakob et al.

Ingår i Journal of clinical pharmacology, s. 905-917, 2022.

DOI för Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma Ladda ner fulltext (pdf) av Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma

Open access
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

Mudde, Saskia E.; Ayoun Alsoud, Rami; van der Meijden, Aart; Upton, Anna M. et al.

Ingår i Journal of Infectious Diseases, s. 1876-1885, 2022.

DOI för Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data Ladda ner fulltext (pdf) av Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

Open access
Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue: Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations

Öbrink-Hansen, Kristina; Pham, Anh Duc; Bue, Mats; Hanberg, Pelle et al.

Ingår i Pharmaceutical research, s. 1633-1643, 2022.

DOI för Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue: Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections

Arrazuria, Rakel; Kerscher, Bernhard; Huber, Karen E.; Hoover, Jennifer L. et al.

Ingår i Frontiers in Microbiology, 2022.

DOI för Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections Ladda ner fulltext (pdf) av Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections

Open access
Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia

Aranzana-Climent, Vincent; Hughes, Diarmaid; Cao, Sha; Tomczak, Magdalena et al.

Ingår i Clinical Microbiology and Infection, s. 1367-1374, 2022.

DOI för Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia Ladda ner fulltext (pdf) av Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia

Open access
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose

Zhao, Chenyan; Chirkova, Anna; Rosenborg, Staffan; Palma Villar, Rodrigo et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2718-2728, 2022.

DOI för Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose Ladda ner fulltext (pdf) av Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose

Open access
Research priorities towards precision antibiotic therapy to improve patient care

Bulman, Zackery P.; Wicha, Sebastian G.; Nielsen, Elisabet I.; Lenhard, Justin R. et al.

Ingår i LANCET MICROBE, s. e795-e802, 2022.

DOI för Research priorities towards precision antibiotic therapy to improve patient care Ladda ner fulltext (pdf) av Research priorities towards precision antibiotic therapy to improve patient care

Open access
Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia

Dreesen, Erwin; Gijsen, Matthias; Elkayal, Omar; Annaert, Pieter et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2479-2488, 2022.

DOI för Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia
Bayesian forecasting of tumor size metrics and overall survival

Krishnan, Sreenath M.; Friberg, Lena E.

Ingår i CPT, s. 1604-1613, 2022.

DOI för Bayesian forecasting of tumor size metrics and overall survival Ladda ner fulltext (pdf) av Bayesian forecasting of tumor size metrics and overall survival

Open access
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

Faraj, Alan; Knudsen, Tom; Desai, Shraddha; Neuman, Linda et al.

Ingår i CPT, s. 1628-1637, 2022.

DOI för Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug Ladda ner fulltext (pdf) av Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

Open access
Pharmacometrics in tuberculosis: progress and opportunities

Wilkins, Justin J.; Svensson, Elin; Ernest, Jacqueline P.; Savic, Radojka M. et al.

Ingår i International Journal of Antimicrobial Agents, 2022.

DOI för Pharmacometrics in tuberculosis: progress and opportunities Ladda ner fulltext (pdf) av Pharmacometrics in tuberculosis: progress and opportunities

Open access
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects

Minichmayr, Iris; Aranzana-Climent, Vincent; Friberg, Lena

Ingår i International Journal of Antimicrobial Agents, 2022.

DOI för Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects Ladda ner fulltext (pdf) av Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects

Open access
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial

Upton, Caryn M.; Van Wijk, Rob C; Mockeliunas, Laurynas; Simonsson, Ulrika S. H. et al.

Ingår i eClinicalMedicine, 2022.

DOI för Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial Ladda ner fulltext (pdf) av Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial

Open access
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1

Sánchez, Javier; Nicolini, Valeria; Fahrni, Linda; Waldhauer, Inja et al.

Ingår i AAPS Journal, 2022.

DOI för Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1
Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival

Sennefelt Nyman, Sofi; Ahlström, Håkan; Dimopoulou, Angeliki; Dahlgren, David et al.

Ingår i BMJ Open, 2022.

DOI för Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival Ladda ner fulltext (pdf) av Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival

Open access
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)

Ekqvist, David; Bornefall, Anna; Augustinsson, Daniel; Sönnerbrandt, Martina et al.

Ingår i BMJ Open, 2022.

DOI för Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP) Ladda ner fulltext (pdf) av Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)

Open access
A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Germovsek, Eva; Hansson, Anna; Karlsson, Mats O.; Westin, Ake et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 416-423, 2021.

DOI för A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Open access
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future

Rayner, Craig R.; Smith, Patrick F.; Andes, David; Andrews, Kayla et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 867-891, 2021.

DOI för Model-Informed Drug Development for Anti-Infectives: State of the Art and Future Ladda ner fulltext (pdf) av Model-Informed Drug Development for Anti-Infectives: State of the Art and Future

Open access
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

Daitch, Vered; Paul, Mical; Daikos, George L.; Durante-Mangoni, Emanuele et al.

Ingår i BMC Infectious Diseases, 2021.

DOI för Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity Ladda ner fulltext (pdf) av Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

Open access
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Minichmayr, Iris K.; Karlsson, Mats O.; Jönsson, Siv

Ingår i Pharmaceutical research, s. 593-605, 2021.

DOI för Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety Ladda ner fulltext (pdf) av Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Open access
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision

Rowland Yeo, Karen; Hennig, Stefanie; Krishnaswami, Sriram; Strydom, Natasha et al.

Ingår i CPT, s. 649-657, 2021.

DOI för CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision Ladda ner fulltext (pdf) av CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision

Open access
Pivotal Role of Translation in Anti-Infective Development

Friberg, Lena E.

Ingår i Clinical Pharmacology and Therapeutics, s. 856-866, 2021.

DOI för Pivotal Role of Translation in Anti-Infective Development Ladda ner fulltext (pdf) av Pivotal Role of Translation in Anti-Infective Development

Open access
Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin

Sou, Tomás; Hansen, Jon; Liepinsh, Edgars; Backlund, Maria et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 1063-1073, 2021.

DOI för Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin Ladda ner fulltext (pdf) av Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin

Open access
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.

Davies Forsman, Lina; Niward, Katarina; Kuhlin, Johanna; Zheng, Xubin et al.

Ingår i European Respiratory Journal, 2021.

DOI för Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.

Open access
Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice

Becker, Katja; Aranzana-Climent, Vincent; Cao, Sha; Nilsson, Anna et al.

Ingår i Clinical Microbiology and Infection, s. 1315-1321, 2021.

DOI för Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice Ladda ner fulltext (pdf) av Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice

Open access